COVID-19: Remdesivir: Early Use in Search for its Niche

Remdesivir has been added to the FDA Emergency Use Authorization list for the treatment of hospitalized patients with severe COVID-19 disease. As such, pharmacists may have questions about the practical and operational aspects of the procurement and utilization of this medication.  This podcast focuses on investigational drug services, dose conservation, and clinical experiences with remdesivir.  In order to learn more about early information on the clinical use of and access to Remdesivir for the treatment of patients with COVID-19, please see the full webinar recording at ASHP elearning.org.

*Recorded on 5/13

The information presented during the podcast reflects solely the opinions of the presenter.  The information and materials are not, and are not intended as, a comprehensive source of drug information on this topic. The contents of the podcast have not been reviewed by ASHP, and should neither be interpreted as the official policies of ASHP, nor an endorsement of any product(s), nor should they be considered as a substitute for the professional judgment of the pharmacist or physician.